- Home
- GBCI vs ACAD Comparison
GBCI vs ACAD Comparison
Compare GBCI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBCI
- ACAD
- Stock Information
- Founded
- GBCI 1955
- ACAD 1993
- Country
- GBCI United States
- ACAD United States
- Employees
- GBCI N/A
- ACAD N/A
- Industry
- GBCI Major Banks
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- GBCI Finance
- ACAD Health Care
- Exchange
- GBCI Nasdaq
- ACAD Nasdaq
- Market Cap
- GBCI 5.1B
- ACAD 4.3B
- IPO Year
- GBCI N/A
- ACAD 2004
- Fundamental
- Price
- GBCI $48.13
- ACAD $24.67
- Analyst Decision
- GBCI Buy
- ACAD Buy
- Analyst Count
- GBCI 6
- ACAD 21
- Target Price
- GBCI $50.50
- ACAD $29.30
- AVG Volume (30 Days)
- GBCI 669.5K
- ACAD 1.8M
- Earning Date
- GBCI 10-23-2025
- ACAD 11-05-2025
- Dividend Yield
- GBCI 2.74%
- ACAD N/A
- EPS Growth
- GBCI 17.64
- ACAD 615.00
- EPS
- GBCI 1.93
- ACAD 1.33
- Revenue
- GBCI $855,046,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- GBCI $16.01
- ACAD $14.01
- Revenue Next Year
- GBCI $25.89
- ACAD $11.72
- P/E Ratio
- GBCI $25.01
- ACAD $18.55
- Revenue Growth
- GBCI 11.62
- ACAD 14.41
- 52 Week Low
- GBCI $36.76
- ACAD $13.40
- 52 Week High
- GBCI $60.67
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- GBCI 53.17
- ACAD 49.69
- Support Level
- GBCI $48.18
- ACAD $23.34
- Resistance Level
- GBCI $49.18
- ACAD $25.90
- Average True Range (ATR)
- GBCI 0.94
- ACAD 0.78
- MACD
- GBCI -0.15
- ACAD -0.28
- Stochastic Oscillator
- GBCI 10.71
- ACAD 40.18
About GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.